Review
Infectious Diseases
Marta Alonso-Moreno, Marta Mejias-Trueba, Laura Herrera-Hidalgo, Walter Alfredo Goycochea-Valdivia, Maria Victoria Gil-Navarro
Summary: The use of continuous infusion of vancomycin (CIV) in the pediatric population is increasing, but data on its efficacy and safety remains limited. Studies suggest pharmacokinetic advantages for CIV, but further research is needed to determine the best administration method for this antibiotic in children.
Article
Infectious Diseases
Sarah Tournayre, Olivier Mathieu, Maxime Villiet, Noemie Besnard, Vincent Brunot, Delphine Daubin, Laura Platon, Philippe Corne, Kada Klouche, Romaric Larcher
Summary: This retrospective cohort study compares the plasma concentrations of meropenem achieved with continuous infusion and extended intermittent infusion in ICU patients, finding that continuous infusion is more effective in achieving the target concentration.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Immunology
Xiangqing Song, Mi Han
Summary: This study evaluated the PK/PD exposure of vancomycin in MRSA bloodstream infections using different infusion modes. The results showed that the optimal two-step infusion (OTSI) mode had advantages in terms of both efficacy and safety, especially for patients with a creatinine clearance (CLcr) of >= 60 ml/min and isolates with an MIC of <= 2 mg/L.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Microbiology
Vasiliki Koumaki, Aristides Dokoumetzidis, Maria Galini Faidra Angelerou, Stavroula Baka, Indran Balakrishnan, Athanasios Tsakris
Summary: This study aims to determine the dosage recommendations for the treatment of urosepsis and infections caused by multidrug-resistant pathogens. The results indicate that 1,000 mg three times a day and 1,000 to 1,200 mg four times a day regimens of intravenous mecillinam are effective against different types of pathogens.
MICROBIOLOGY SPECTRUM
(2023)
Article
Chemistry, Medicinal
Sang-Mi Kim, Hyun-Seung Lee, Na-Young Hwang, Kyunga Kim, Hyung-Doo Park, Soo-Youn Lee
Summary: In non-critically ill patients, utilizing PK-guided dosing through PKCS led to a higher target attainment rate of vancomycin but did not reduce treatment failures, shorten treatment duration, or decrease nephrotoxicity in vancomycin therapy. More selective criteria for individualized pharmacokinetic-guided dosing are needed due to the excessive efforts currently put into vancomycin dosing and monitoring.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Infectious Diseases
Chailat Maluangnon, Surat Tongyoo, Chairat Permpikul
Summary: This study compared the benefits of continuous and intermittent vancomycin infusion. Continuous infusion was found to achieve therapeutic targets faster and have fewer subtherapeutic episodes compared to intermittent infusion. However, there was no significant difference in treatment success, mortality, or incidence of acute kidney injury between the two methods.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Immunology
Thomas J. Dilworth, Lucas T. Schulz, Warren E. Rose
Summary: Vancomycin therapy often involves empirical use without the necessity of AUC monitoring. Guidelines recommending AUC monitoring are based on limited evidence and should be used cautiously.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Pier Giorgio Cojutti, Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Cristiana Laici, Chiara Mega, Antonio Siniscalchi, Maddalena Giannella, Pierluigi Viale, Federico Pea
Summary: The study demonstrates that maintaining Css/MIC ratio >= 4.63 may be crucial for the efficacy of treating Gram-negative infections in critically ill patients. Different dosages of meropenem administered via continuous infusion could enhance pathogen susceptibility and show high clinical response rates under varying renal function levels.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Infectious Diseases
Eliel Nham, Kyungmin Huh, You Min Sohn, Hyo Jung Park, Hyemee Kim, Sook Young Woo, Jae-Hoon Ko, Sun Young Cho, Cheol-In Kang, Doo Ryeon Chung, Hee Jae Huh, Hyung-Doo Park, Nam Yong Lee, Kyong Ran Peck
Summary: This study aimed to investigate the pharmacokinetic/pharmacodynamic parameters of vancomycin that are associated with the optimal outcome of severe infection caused by Enterococcus species. The findings revealed that a mean trough concentration of vancomycin greater than or equal to 13.94 μg/mL during the initial 72 hours of treatment was significantly associated with higher 30-day mortality in enterococcal bacteremia.
BMC INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Summary: A pharmacokinetic/pharmacodynamic (PK/PD) analysis was performed on the combination therapy of continuous-infusion fosfomycin with extended-infusion cefiderocol or continuous-infusion ceftazidime-avibactam for severe difficult-to-treat Pseudomonas aeruginosa infections. The study found that achieving optimal joint PK/PD targets could result in favorable microbiological outcomes in patients with these infections.
Article
Infectious Diseases
Pasquale Maria Berrino, Milo Gatti, Matteo Rinaldi, Eugenio Brunocilla, Pierluigi Viale, Federico Pea
Summary: This study explores the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem monotherapy and microbiological outcome in urological patients with Gram-negative infections. The results demonstrate that optimizing beta-lactam treatment through real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program can achieve microbiological eradication in most cases.
Article
Microbiology
Praneeth Jarugula, Ayse Akcan-Arikan, Flor Munoz-Rivas, Brady S. Moffett, Vijay Ivaturi, Danielle Rios
Summary: This study aimed to determine the optimal vancomycin starting dose regimens in infants <= 180 days of age to achieve the highest probability of target attainment with AUC(24) of >= 400. It also examined the relationship between serum creatinine and vancomycin clearance in neonates.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Jihui Chen, Xiaohui Huang, Zhiyan Lin, Chao Li, Haoshu Ding, Junming Du, Lixia Li
Summary: Limited PK studies on vancomycin in CRRT patients show inconsistent results, making it difficult to propose a definite clinical recommendation. Rapidly achieving target vancomycin concentrations is essential for effective treatment. Monitoring vancomycin blood concentrations and developing individualized dosing regimens based on real-time therapeutic drug monitoring results and PK parameters can lead to good clinical efficacy in critically ill patients undergoing CVVH.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Infectious Diseases
Passara Maimongkol, Wanlika Yonwises, Suvaporn Anugulruengkitt, Jiratchaya Sophonphan, Wanchai Treyaprasert, Noppadol Wacharachaisurapol
Summary: This study compared the unbound plasma meropenem concentrations and proportions of achieving minimum inhibitory concentration (MIC) in children receiving extended infusion (EI) and intermittent bolus (IB) administration in a therapeutic drug monitoring program.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Critical Care Medicine
Cory J. Schlobohm, Elizabeth Zhu, Jeremiah J. Duby
Summary: The study indicated that continuous infusion of vancomycin was associated with more rapid attainment of target levels and a lower rate of nephrotoxicity.
Article
Microbiology
Laetitia G. Garcia, Sandrine Lemaire, Barbara C. Kahl, Karsten Becker, Richard A. Proctor, Paul M. Tulkens, Francoise Van Bambeke
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2012)
Article
Microbiology
Julien M. Buyck, Paul M. Tulkens, Francoise Van Bambeke
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2013)
Article
Microbiology
Julia Bauer, Wafi Siala, Paul M. Tulkens, Francoise Van Bambeke
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2013)
Article
Immunology
Julien M. Buyck, Patrick Plesiat, H. Traore, F. Vanderbist, Paul M. Tulkens, Francoise Van Bambeke
CLINICAL INFECTIOUS DISEASES
(2012)
Article
Immunology
Beverlie Baquir, Sandrine Lemaire, Francoise Van Bambeke, Paul M. Tulkens, Lin Lin, Brad Spellberg
CLINICAL INFECTIOUS DISEASES
(2012)
Article
Geriatrics & Gerontology
Coraline Claeys, Jean Neve, Paul M. Tulkens, Anne Spinewine
Article
Infectious Diseases
Ann Lismond, Sylviane Carbonnelle, Jan Verhaegen, Patricia Schatt, Annelies De Bel, Paul Jordens, Frederique Jacobs, Anne Dediste, Frank Verschuren, Te-Din Huang, Paul M. Tulkens, Youri Glupczynski, Francoise Van Bambeke
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2012)
Letter
Infectious Diseases
Julien M. Buyck, Sophie Guenard, Patrick Plesiat, Paul M. Tulkens, Francoise Van Bambeke
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2012)
Article
Infectious Diseases
Aurelie Melard, Laetitia G. Garcia, Debaditya Das, Raoul Rozenberg, Paul M. Tulkens, Francoise Van Bambeke, Sandrine Lemaire
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2013)
Article
Infectious Diseases
Laetitia G. Garcia, Sandrine Lemaire, Barbara C. Kahl, Karsten Becker, Richard A. Proctor, Paul M. Tulkens, Francoise Van Bambeke
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2012)
Article
Infectious Diseases
Violeta Raverdy, Els Ampe, Jean-Daniel Hecq, Paul M. Tulkens
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2013)
Review
Infectious Diseases
Laetitia G. Garcia, Sandrine Lemaire, Barbara C. Kahl, Karsten Becker, Richard A. Proctor, Olivier Denis, Paul M. Tulkens, Francoise Van Bambeke
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2013)
Article
Biochemistry & Molecular Biology
Marie-Paule Mingeot-Leclercq, Paul M. Tulkens, Sophie Denamur, Timo Vaara, Martti Vaara
Article
Multidisciplinary Sciences
Nancy E. Caceres, Maarten Aerts, Beatrice Marquez, Marie-Paule Mingeot-Leclercq, Paul M. Tulkens, Bart Devreese, Francoise Van Bambeke
Review
Infectious Diseases
Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman
Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)
Article
Infectious Diseases
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri
Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)